Biotricity Receives Research Grant to Study Next Generation Heart Rate Variability for Preventative Medicine Applications
Toronto, Canada and Redwood City, California -- February 22, 2016 – Biotricity (OTCQB: BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has been awarded a research grant from the National Research Council-Industrial Research Assistance Program (NRC-IRAP) of Canada. The prestigious grant enables Biotricity to conduct research around the use of heart rate variability (HRV) in various applications for preventative medicine.
"HRV has been a research tool rather than a clinical tool for decades, but has the ability to predict the onset of a number of life-threatening disease states including strokes, heart attacks, sleep apnea, sepsis, etc.," said Dr. David Liepert, a University of Calgary professor and anesthesiologist at Rockyview General Hospital. "However, it is not mobile. HRV data collection mandates that patients be connected to a monitor, which has precluded the development of most clinical utilities. The next generation technology that we are researching and developing in this study and others will address this issue, and my research will focus on taking this approach to the next level."
The research will be led by Biotricity's principal investigator Dr. David Liepert, who is collaborating with the University of Calgary and the Rockyview General Hospital. The NRC-IRAP is Canada's premier technology assistance program for small and medium-sized enterprises, and a cornerstone in Canada's innovation system that is regarded world-wide as one of the best programs of its kind.
The lack of patient compliance continues to be both a challenge and a cost driver due, in part, to the lack of mobile and clinical-grade medical devices available. For instance, once a patient has been diagnosed with a condition, they will need to monitor their health on an ongoing basis. According to an article in the Journal of Risk Management & Healthcare Policy, poor patient compliance costs the U.S. healthcare system $100 to $300 billion annually, representing 3-10 percent of total U.S. healthcare costs. This is due to the lack of feedback mechanisms available to indicate and measure improvement, leading to a reluctance in patients to engage in preventative care measures. By developing devices that provide quantifiable feedback to measure clinical improvement, patients will have a better understanding of their health issues and will be more inclined to proactively manage their overall wellness.
"Government and healthcare organizations are focused on driving costs down by shifting to evidence-based healthcare where individuals, especially those suffering from chronic illnesses, engage in self-management and preventative care," said Waqaas Al-Siddiq, founder, president and CEO of Biotricity. "We are thrilled to receive such an important grant and am confident that our research with Dr. Liepert will drive the development of our next-generation medical devices that are capable of disrupting how clinical grade data is captured and used by both patients and health care professionals to support evidence based healthcare and reduce costs."
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
McCoin & Smith Communications Inc.
Liolios Group, Inc.